<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052584</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCZVED-5628</org_study_id>
    <nct_id>NCT01052584</nct_id>
  </id_info>
  <brief_title>Ethiopia Malaria Therapeutic Efficacy Study</brief_title>
  <official_title>Ethiopia In-vivo Efficacy Study 2009: Evaluating the Efficacy of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Infection and Either Artemether-lumefantrine or Chloroquine for P. Vivax Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Agency for International Development (USAID)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this stdy, patients aged above 6 months with symptomatic malaria presenting to health&#xD;
      centers will be enrolled for treatment with artemether-lumefantrine for P. falciparum&#xD;
      infection, and either artemether-lumefantrine or chloroquine for P. vivax infection.&#xD;
      Clinical, parasitologic, and hematologic parameters will be monitored for P. falciparum and&#xD;
      P. vivax infection over a 42-day follow-up period, which will be used to evaluate drug&#xD;
      efficacy. Results from this research study will be used to assist Ethiopia in assessing their&#xD;
      current national malaria drug policies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following the rapid development of significant drug resistance of Plasmodium falciparum (Pf)&#xD;
      to chloroquine and then sulfadoxine-pyrimethamine (the first line therapy in Ethiopia&#xD;
      1998-2004), artemether- lumefantrine (Coartem or AL) was adopted as first line therapy in&#xD;
      Ethiopia in 2004. According to the current national malaria diagnosis and treatment&#xD;
      guidelines, first-line treatment for uncomplicated falciparum infection is AL. First-line&#xD;
      treatment for Plasmodium vivax (Pv) is with chloroquine (CQ) alone without primaquine therapy&#xD;
      in malarious areas. For all clinical infection without laboratory confirmation, AL which is&#xD;
      effective against both Pf and Pv is the first-line treatment. Thus, in Ethiopia, where&#xD;
      treatment for malaria without laboratory confirmation occurs frequently, Pv is often treated&#xD;
      with AL as the standard of care. Furthermore, World Health Organization (WHO) recommends AL&#xD;
      for the treatment of Pv, where AL has been adopted as first-line treatment for Pf. Now with&#xD;
      wide-spread use of AL and CQ, we propose to conduct an antimalarial efficacy study to monitor&#xD;
      the effectiveness of these therapies in Ethiopia and to determine how efficacious these drugs&#xD;
      remain. This information will inform future policy changes with respect to appropriate&#xD;
      antimalarial strategies.&#xD;
&#xD;
      The simplest and most universally accepted measure of testing for antimalarial drug treatment&#xD;
      efficacy, the standardized procedures outlined in the World Health Organization Assessment&#xD;
      and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum&#xD;
      malaria and the WHO Monitoring antimalarial drug resistance, will be followed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine Early Treatment Failures, Late Clinical Failures, Late Parasitological Failures, or Adequate Clinical and Parasitological Response during 28 days of follow-up for P. falciparum. Measure the treatment failure of AL and CQ for P. vivax</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine Early Treatment Failures, Late Clinical Failures, Late Parasitological Failures, or Adequate Clinical and Parasitological Response during 42 days of follow-up for P. falciparum. Measure the treatment failure of AL and CQ for P. vivax durin</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">354</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Chloroquine-P. vivax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P. vivax randomized to receive chloroquine 3-day regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artemether-Lumefantrine: P. vivax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Artemether-lumefantrine: P. falciparum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine- P. vivax</intervention_name>
    <description>Total of 25mg base per kg over 3 days (10 mg base/kg on Days 1 and 2, and 5 mg base/kg on Day 3)</description>
    <arm_group_label>Chloroquine-P. vivax</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-Lumefantrine: P. vivax</intervention_name>
    <description>administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage</description>
    <arm_group_label>Artemether-Lumefantrine: P. vivax</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine: P. falciparum</intervention_name>
    <description>administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage</description>
    <arm_group_label>Artemether-lumefantrine: P. falciparum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Slide-confirmed infection with P. falciparum, with parasitemia of 1,000-100,000&#xD;
             asexual forms/ μl or slide confirmed infection with P. vivax with &gt; 250 asexual forms/&#xD;
             μl&#xD;
&#xD;
          -  Lives within 20 km of the enrolling health facility&#xD;
&#xD;
          -  Weight ≥ 5.0 kg&#xD;
&#xD;
          -  Axillary temperature ≥ 37.5º C or history of fever during the previous 24 or 48 hours&#xD;
             for P. falciparum and P. vivax infection, respectively&#xD;
&#xD;
          -  Patient or caregiver agrees to all blood draws and return visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  General danger signs or symptoms of severe malaria&#xD;
&#xD;
          -  Signs or symptoms of severe malnutrition, defined as weight-for-age ≤ 3 standard&#xD;
             deviations below the mean (NCHS/WHO normalized reference values;&#xD;
&#xD;
          -  Slide confirmed infection with any other Plasmodium spp. besides falciparum/vivax or&#xD;
             mixed plasmodium infection&#xD;
&#xD;
          -  Severe anemia, defined as Hg &lt; 5 g/dl&#xD;
&#xD;
          -  Known hypersensitivity to any of the drugs being evaluated&#xD;
&#xD;
          -  Presence of febrile conditions caused by diseases other than malaria&#xD;
&#xD;
          -  Serious or chronic medical condition (cardiac, renal, hepatic diseases, sickle cell&#xD;
             disease, HIV/AIDS)&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Children weighing less than 5 kilograms.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jimee Hwang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DebreZeit Malaria Center</name>
      <address>
        <city>Debrezeit</city>
        <state>Oromia</state>
        <country>Ethiopia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bulbula Health Center</name>
      <address>
        <city>Zeway</city>
        <state>Oromia</state>
        <country>Ethiopia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ethiopia</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>January 17, 2010</study_first_submitted>
  <study_first_submitted_qc>January 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <last_update_submitted>November 17, 2010</last_update_submitted>
  <last_update_submitted_qc>November 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jimee Hwang/ Medical Epidemiologist</name_title>
    <organization>CDC</organization>
  </responsible_party>
  <keyword>malaria</keyword>
  <keyword>therapeutic efficacy</keyword>
  <keyword>in vivo</keyword>
  <keyword>artemether lumefantrine</keyword>
  <keyword>coartem</keyword>
  <keyword>chloroquine</keyword>
  <keyword>Plasmodium falciparum</keyword>
  <keyword>Plasmodium vivax</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemether, Lumefantrine Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

